The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Successful Trial of PFAS Remediation System

25 Jan 2022 07:00

RNS Number : 4558Z
MyCelx Technologies Corporation
25 January 2022
 

25 January 2022

MYCELX Technologies Corporation

 

Successful Trial of MYCELX's PFAS Remediation System

 

Reduction to non-detect levels highlights significant commercial opportunity

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce that it has successfully completed a trial in the United States of its PFAS remediation system which deploys its patented MYCELX technology. The results of the trial confirm the ability of MYCELX's PFAS remediation system to reduce contamination to non-detect level in a single pass through the system.

 

PFAS, which stands for perfluoroakyl and polyfluoroalkyl compounds, are a collection of long-lasting man-made toxic chemicals, which present a threat to the environment and human health. The Company estimates the annual PFAS remediation cost in the United States to be in excess of US$8bn.

 

As part of its continuing strategy to address the PFAS remediation market, MYCELX commenced an important trial at an industrial site in Newburgh, New York, in December 2021. The trial involved treating PFAS contaminated water from a storm water retention pond. The likely source of the PFAS contamination was aqueous film forming foams (AFFF). The presence of additional contaminants, such as glycols from plane de-icing procedures, ensured a challenging and complex water source to remediate. MYCELX installed a mobile trial system using the patented MYCELX technology for PFAS remediation. Earlier generations of this technology have already been successfully deployed in Australia, which is recognised as being at the forefront of PFAS remediation. The MYCELX solution is designed to offer a lower life-cycle cost of treatment, primarily due to significantly reduced waste versus alternative technologies.

 

The trial successfully demonstrated the ability of the MYCELX system to completely remove all detected chemicals to non-detectable concentrations in a single pass, achieving a 99.99% removal efficiency. Complete removal of this spectrum of PFAS chemicals eliminates both regulated PFAS compounds, and complete removal will prevent future degradation of components into PFAS compounds that may be subject to future regulation. The technology provided a failsafe treatment with no rise in differential pressures or increase in outlet concentrations over the length of the trial.

 

Given the outlook for an increasingly strict regulatory climate for PFAS contamination in North America, MYCELX, which was recently awarded the Green Economy Mark by the London Stock Exchange for its contribution to the global green economy, believes it is well placed to play an important role in the global PFAS remediation challenge.

 

Connie Mixon, CEO of MYCELX, said:

 

"I am delighted to announce a successful outcome at our trial in the United States, which further proves the viability of our PFAS remediation system, and will pave the way for our entry into the US market. Our expansion in Australia continues to gather momentum, with MYCELX technology currently deployed in five commercial operations ranging from airports to military bases and with a global oil supermajor.

 

With reliable and complete remediation of detectable PFAS chemicals, MYCELX provides a breakthrough technological solution to remove a complete range of PFAS types to below detectable levels. We believe this means that the Company's offering not only has a significant technical advantage over its competitors, but at a more cost-effective price point. This test result is an important step forward in progressing towards our first commercial contract for PFAS remediation in the United States."

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity, Nominated Adviser

Henry Fitzgerald-O'Connor

Georgina McCooke

 

 

Tel: + 44 20 7523 8000

Celicourt

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

 

Notes to Editors

 

Through its revolutionary oil-free water technology, MYCELX brings its customers material benefits in terms of performance enhancement, cost savings and significantly improved environmental footprints. Working beyond any ordinary filtration methods, MYCELX's proprietary technology achieves oil removal to less than one part per million. MYCELX supports leading international customers across the oil & gas value chain, as well as other industrial users. MYCELX also provides advanced air filtration technology for manufacturing and industrial facilities, effectively removing oil particles and biologicals to maintain continuous and safe air quality levels.

 

For more information, visit www.MYCELX.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRUSUURUUUAUUR
Date   Source Headline
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.